COMSCIMS
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Mesenchymal stem cells (MSCs)
What it measured
Main measures
Number of Gadolinium positive lesions and / or newly demonstrated or increased T2 lesions (combined unique activity) over a period of 24 weeks after administration of MSCs compared with the control period (24 weeks).
MRI lesions
Other measures (1)
1. Comparison at 48 weeks between early versus late administration of MSCs by:
Who could take part
MS (type not specified)
Inclusion: 1. Inflammatory form of multiple sclerosis (MS) Exclusion: 1. Secondary progressive MS without relapses
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the effect of intra-venously applied autologous MSCs on cerebral inflammation in multiple sclerosis patients
Papers
Loading reviews and guidelines…
Related trials
- A Study of C-CAR168 in the Treatment of Autoimmune Diseas…
Phase 1 · Not yet recruiting
Still running
- A Study of C-CAR168 in the Treatment of Central Nervous S…
Phase 1 · Not yet recruiting
Still running
- Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refra…
Phase 1 · Withdrawn
Stopped early
- Universal CAR-T Cells in Patients with Refractory Autoimm…
Early phase 1 · Not yet recruiting
Still running
- CAR-AID
Phase 1 · Recruiting
Still running
- Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins an…
Status unknown
No result found
History
Started
Jun 2012
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error